STUDY OF EFFICACY OF VISUAL INSPECTION WITH DILUTED ACETIC ACID AND LUGOL’S IODINE FOR EARLY DETECTION OF CERVICAL CANCER

Acharya Veena¹, Naruka Nisha², Joshi Leena³, Meena Ashok⁴, Mathur Abha⁵

HOW TO CITE THIS ARTICLE:
Acharya Veena, Naruka Nisha, Joshi Leena, Meena Ashok, Mathur Abha. “Study of Efficacy of Visual Inspection with Diluted Acetic Acid and Lugol's Iodine for Early Detection of Cervical Cancer”. Journal of Evolution of Medical and Dental Sciences 2014; Vol. 3, Issue 28, July 14; Page: 7905-7910, DOI: 10.14260/jemds/2014/2989

ABSTRACT: AIMS AND OBJECTIVE: Screening of women, of 30-50 years age, by doing VIA and VILI, Colposcopy and Treatment by Cryotherapy and LEEP in Histopathological positive cases in mahatma Gandhi Medical College and Hospital, Jaipur from 2010 to 2013. METHODS: Study was hospital based Total number of women screened were 834, who were attending regular outdoor in Mahatma Gandhi Medical Hospital for any gynecological complaints. Age group was 30-50 years; women were not pregnant and not menstruating. Out of 834 subjects, 21 subjects refused for VIA and Colposcopy, only VILI was done in these cases. RESULTS: This study was carried out during Jan 2010 to March 2013. A total of 834 women were recruited, 21 women refused for VIA and colposcopy. Out of 834 cases, in 4 cases SCJ (Squamo Columnar Junction) not seen, in 98% women SCJ seen fully. Out of 834, 225 (27%) cases were VILI positive and out of 813, 184 cases i.e. 22.6% were Via positive Biopsy was taken in 223 cases where HSIL reported in 3 cases (1.4%) and invasive squamous cell carcinoma in 4 cases. Out of 834 women, cryotherapy was done in 61 cases and LEEP in 15 cases, conization in 1andsurgery in 3 cases. CONCLUSION: Visual screening has been taken as most effective method as compared to cytology or HPV testing. It is cheap, outdoor procedure, can be done by paramedical staff and can be done in large scale.

KEYWORDS: Visual inspection, acetic acid, lugol's Iodine, VIA, VILI, sensitivity, specificity, cervical neoplasia, screening.

INTRODUCTION: Cancer of Cervix Uteri is the most common cancer among women in developing world, and 60% of all cases occur in the countries of Sub-Saharan Africa, South Asia and Latin America¹. Cervical cytology screening programme in developed countries has reduced disease burden to some extent. Screening programme exist in few countries where to some extent reduction in mortality from cervical cancer has been observed²-³. Success of screening program by cytology mostly depends upon skilled personnel, good quality cytology smears, good laboratory facility and good organization which are a big hindrance in screening program. In developing countries like in India with poor resource setting, simple and cheap methods like VIA, VILI are effective methods of screening women for prevention of cervical cancer.

Number of cross sectional studies conducted in India and Africa by IARC (International Agency for Research on Cancers) in collaboration with national institution to know the accuracy of VIA and VILI to detect HSIL (high grade cervical intra epithelial neoplasia)⁴.

STUDY DESIGN: During the years 2010 to 2013, the study of cervical cancer screening was conducted in Mahatma Gandhi Medical College and Hospital, Sitapura, Jaipur (Rajasthan). Simple protocol was used.
All women participating in the study were tested with index screening tests VIA and VILI and reference investigation, namely colposcopy with or without biopsy, biopsies were taken in women with abnormal or suspicious finding on colposcopy. All the testing were done independently and blinded. True positive disease was defined as HSIL a gold standard was histopathology.

PARTICIPANTS: The study participants were healthy, ambulant, asymptomatic women who were aged 30-50 years with an intact uterus with no past history of cervical neoplasia. Women who had non satisfactory colposcoby with no biopsy were excluded from the study. Women attended open access screening program, a female health worker explained the purpose of the study. A printed consent form was read in front of participants and duly signed by them. After the interview, screening tests and diagnostic investigation were carried out.

TEST METHODS: VIA and VILI were performed by trained female health workers under supervision of doctor. Health workers and medical professionals were given a training of VIA and VILI and colposcopy using lectures, discussions, review of photographs of normal and abnormal cervix. In outdoor, each participant was tested with VIA followed by colposcopy and VILI was placed in a modified lithotomy position on an examination table. Cervix was exposed by inserting a bivalve speculum. After application of 4% acetic acid to cervix, it is examined after a minute using a halogen lamp light source and then colposcopy in done. In VIA positive cases, VILI was done and punch biopsy taken from abnormal area and sent for histopathological exam.

Final diagnosis was based on histopathology i.e. it was taken as gold standard to find out true disease. However when histology is not available or is not conclusive colposcopy diagnosis may be taken as the true disease, for cervical neoplasia, colposcopy and directed biopsy are commonly used and are accepted reference standard ("gold standard") investigations. If histology is not available then colposcopic diagnosis may be accepted as true disease.

STATISTICAL METHODS: HSIL were considered as true positive disease to calculate sensitivity, specificity and predictive values of the screening tests in order to obtain conservative estimates of accuracy and to avoid spectrum bias.

RESULTS:

PARTICIPANTS: My study was carried out during Jan 2010 to March 2013. A total of 834 women who were attending Gynae outdoor were recruited, out of 834 women, 21 women refused for VIA and Colposcopy and only VILI was done in these cases.

| Squamocolumnar Junction | Cases number | %  |
|--------------------------|--------------|----|
| 1. Yes, fully            | 817          | 98%|
| 2. Yes, Partially        | 13           | 1.6%|
| 3. No                    | 4            | 0.5%|
| **Total**                | **834**      | **100%**|

TABLE 1

Squamocolumnar Junction Frequency:
As the Table 1 suggests, out of 834, squamocolumnar junction was fully visualized in 817 women i.e. 98%. In 4 women, squamocolumnar junction was not fully visualized and in 13 women SCJ was partially visualized.

**TABLE 2 (screening tests with VIA and VILI)**

| VILI Results | Cases Number | %  |
|--------------|--------------|----|
| 1. Negative  | 609          | 73%|
| 2. Positive  | 225          | 27%|
| 3. Invasive cancer | 0   | 0% |
| TOTAL        | 834          | 100%|

Findings of VILI Results

| VIA Results | Cases Number | %  |
|-------------|--------------|----|
| 1. Negative | 629          | 77.4%|
| 2. Positive | 184          | 22.6%|
| 3. Unknown  | 0            | 0% |
| TOTAL       | 813          | 100%|

Findings of VIA Results

VIA was positive in 184 women i.e. 22.6% and VILI was positive in 225 women i.e. 27%. Test positivity was related to visibility of SCJ, age, menstrual status, education, marital status and Pregnancies.

Out of VIA positive 176 cases, 124 were normal 70%
22 had low grade lesions i.e. 12% and 6 have HSIL i.e. 3%

Among women tested with VILI out of 163 VILI positive women, normal were 128 i.e. 78%, 18 had low grade lesions i.e. 11% and 5 have HSIL i.e. 3%.

Women were treated after results of Histopathology because it was Gold standard test. No adverse reaction such as bleeding as allergic reaction was noted in the study.

**TABLE 3: histopathology of VIA test**

| HISTO                          | 1. Negative | 2. Positive | 3. Invasive cancer | Total | %  |
|--------------------------------|-------------|-------------|--------------------|-------|----|
| 0. Not done                    | 0           | 0           | 0                  | 0     | 0% |
| 1. Inflammation / chronic cervicitis | 4          | 15          | 19                 | 19    | 8.5% |
| 2. Squamous metaplasia         | 23          | 87          | 110                | 110   | 49.5% |
| 3. HPV infection               | 4           | 18          | 22                 | 22    | 10% |
| 4. Atypia                      | 0           | 4           | 4                  | 4     | 2% |
| 5. CIN 1                       | 2           | 22          | 24                 | 24    | 11% |
| 6. CIN 2                       | 0           | 2           | 2                  | 2     | 0.9% |
| 7. CIN 3                       | 0           | 1           | 1                  | 1     | 0.45% |
| 8. Early invasive carcinoma    | 0           | 2           | 2                  | 2     | 0.9% |
| 9. Invasive squamous cell carcinoma | 1           | 1           | 2                  | 2     | 0.9% |
Sensitivity of VIA in detecting HSIL was 86% and sensitivity was 78%, positive predictive value PPV 3.2% and negative predictive value NPV 99.8%.

**TABLE 4: histopathology of VILI test**

| HISTO                                    | 1. Negative | 2. Positive | 3. Invasive cancer | Total | %   |
|------------------------------------------|-------------|-------------|--------------------|-------|-----|
| 0. Not done                              | 0           | 0           | 0                  | 0     | 0%  |
| 1. Inflammation / chronic cervicitis     | 4           | 15          | 19                 | 8.5%  |
| 2. Squamous metaplasia                   | 26          | 84          | 110                | 49.5% |
| 3. HPV infection                         | 6           | 16          | 22                 | 10%   |
| 4. Atypia                                | 1           | 3           | 4                  | 2%    |
| 5. CIN 1                                 | 6           | 18          | 24                 | 11%   |
| 6. CIN 2                                 | 0           | 2           | 2                  | 0.9%  |
| 7. CIN 3                                 | 0           | 1           | 1                  | 0.45% |
| 8. Early invasive carcinoma              | 0           | 2           | 2                  | 0.9%  |
| 9. Invasive squamous cell carcinoma      | 2           | 0           | 2                  | 0.9%  |
| 10. Invasive adenocarcinoma              | 0           | 0           | 0                  | 0%    |
| 99. Other                                | 15          | 22          | 37                 | 16.6% |
| **Total**                                | **60**      | **163**     | **223**            | **100.0%** |

Sensitivity of VILI in detecting HSIL were 71.43% specificity- 73.4%, PPV – 2.25%, NPV-99.8%
DISCUSSION: A screening test is suitable only because of its simplicity and safety and its accuracy which is measured by sensitivity and specificity\(^\text{10}\).

A suitable reference test should distinguish the subjects who are truly positive from those who are negative. A study will suffer from “verification bias” if the reference investigation is restricted to test positive individuals only to a sample of test negative persons. Such bias is known to inflate sensitivity estimates and maybe avoided if all individuals receive the reference investigation, irrespective of the test results\(^\text{11}\). Previous cross-sectional studies\(^s\text{7,12-20}\) have reported on the accuracy of VIA but all except 2 studies\(^s\text{7,13}\) suffered from verification bias. There are no published results for VILI in recent decades but VILI had significantly higher sensitivity and specificity than those reported for VIA in the Zimbabwe\(^7\) and chinese\(^13,14\) studies.

The characteristics of VIA as a screening test have been established by many cross sectional studies, VILI is used to detect color pattern by health workers.

Though sensitivity and specificity of VIA and VILI have not much far difference but if compared VIA is more specific, cheap and simple procedure. It can be done in outdoor by paramedical staff also and can be used for large population.

REFERENCES:

1. Parkin D.N, Bray F.L, Devessi S.S, cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37:54-60
2. Sankarnarayanan R, Budukh A, Rajkumar R, Effective Screening Programmes for cervical cancer in low and middle income developing countri.e.s, Bull World Health Org. 2001;79:954-62
3. Robles SC, White F, Peruga A. Trends in cervical cancer mortality in the America. Bull pan Am Health Organ 1996; 30:290-301
4. Sankarnarayanan R, Wesley R. A practical manual on visual screening for cervical neoplasia: Lyon: International Agency for research on cancer, IARC press 2003; Technical publication no.41.
5. Sellors J, Sankarnarayanan R. colposcopy and treatment of cervical intraepithelial neoplasia: a beginners' manual: IARC non-serial publication. Lyon : IARC press, 2003
6. Mitchell MF, Schottenfeld D, Tortolera-Luna G, Cantor SB, Richards-Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 91:626-31
7. University of Zimbabwe JHPI.E. GO Cervical cancer project. Visual inspection with ascetic acid for cervical cancer screening: test qualities in a primary care setting. Lancet 1999; 353:869-73
8. Coppleson M, Dalrymple JC, Atkinson KH, Colposcopic differentiation of abnormalities arising in the transformation zone. Obstet gynecol Clin North Am 1993; 20:83-110
9. Santos Silva I. Cancer epidemiology, principles and methods. Lyon: International Agency for research on cancer, 1999
10. Wilson JMG, Jungner G. Principles and practice of screening for disease. Public health Papers no34. Geneva: WHO, 1968
11. Choi BCK. Sensitivity and specificity of a single diagnostic test in the presence of work up bias. J Clin Epidemiol 1992; 45:581-6
12. Schiller W. Early diagnosis of Carcinoma of the cervix. Surg Gynecol Obstet 1933; 66:210-20
13. Belinson JL, Pretorius RG, Qiao YL, Zhang WH, Elson P, Li L, Pan QJ, Fischer c, Lorincz A, Zahnister D. Shanxi province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynaecol oncol 2001; 83:439-44
14. Belinson JL, Pretorius RG, Zhang WH, Wu Ly, Qiao YL, Elson P. Cervical cancer screening by simple visual inspection after acetic acid. Obstet Gynecol 2001; 98:441-4
15. Sankarnarayanan R, Wesley R, Somanathan T, Dhakad N, Parkin DM et al, a Visual inspection of the uterine cervix after the application of ascetic acid in the detection of cervical carcinoma and its precursors, 1998; 83:2150-6
16. Sankarnarayanan R, Shyalakumari B, Wesley R, Sreedevi Amma, Krishnan Nair M. Visual inspection with acetic acid in the early detection of cervical cancer, 1999; 80:161-3
17. Cecchini S, Bonardi R, Mazzotta A, Grazzini G, Iossa A, Ciato S. testing cervicography and cervicoscopy as screening tests for cervical cancer, 1993;79:22-5
18. Megavand E, Denny L, Dehaeck, Soeters R, Bloch B. acetic acid visualization of the cervix: an alternative to cytologic screening. Obst and Gynaec 1996; 88:383-6
19. Denny L, Kuhn I, Pollack A, Wainwright H. Evaluation of alternative methods of cervical cancer screening in poor resource settings, 2000; 89:826-33
20. Denny L, Kuhn L, Pollack A, Wright TC jr. Direct visual inspection for cervical cancer screening 2002; 94:1699-707

AUTHORS:
1. Acharya Veena
2. Naruka Nisha
3. Joshi Leena
4. Meena Ashok
5. Mathur Abha

PARTICULARS OF CONTRIBUTORS:
1. Professor, Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College & Hospital, Sitapura, Jaipur.
2. Assistant Professor, Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College & Hospital, Sitapura, Jaipur.
3. Senior Resident, Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College & Hospital, Sitapura, Jaipur.
4. Junior Resident, Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College & Hospital, Sitapura, Jaipur.
5. Professor, Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College & Hospital, Sitapura, Jaipur.

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Dr. Naruka Nisha,
House No. 2,
Tyagi Colony,
Gopalpura Turn,
Tonk Road,
Jaipur, Rajasthan.
Email: nisha_naruka@yahoo.com

Date of Submission: 26/04/2014.
Date of Peer Review: 28/04/2014.
Date of Acceptance: 07/05/2014.
Date of Publishing: 14/07/2014.